CPRX — Catalyst Pharmaceuticals Balance Sheet
0.000.00%
- $2.52bn
- $1.86bn
- $491.73m
- 99
- 74
- 36
- 80
Annual balance sheet for Catalyst Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 140 | 191 | 298 | 138 | 518 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.99 | 6.62 | 10.4 | 53.5 | 65.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 159 | 210 | 321 | 219 | 624 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.13 | 3.98 | 3.62 | 3.7 | 3.58 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 192 | 238 | 376 | 470 | 851 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 22.8 | 27.1 | 57.6 | 76.1 | 121 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 22.8 | 31 | 75.2 | 82.2 | 124 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 170 | 207 | 300 | 388 | 728 |
| Total Liabilities & Shareholders' Equity | 192 | 238 | 376 | 470 | 851 |
| Total Common Shares Outstanding |